|
5-MAPDB
5-MAPDB (1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine) is a chemical compound which acts as an entactogenic drug. It is structurally related to drugs like 5-APDB and 5-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 5-MAPDB has been studied to determine its pharmacological activity, and was found to be a relatively selective serotonin releaser, though with weaker actions as a releaser of other monoamines and 5-HT2 receptor family agonist, similar to older compounds such as 5-APDB. Legality 5-MAPDB was banned in the UK in June 2013 as a temporary class drug along with 9 other related compounds, despite having never been sold as a street drug itself. This was due to concerns that it would have similar effects to drugs such as 5-APB that had been widely sold already, and 5-MAPDB might therefore be likely to become used recreationally also, if it were not banned preemptively. See also * 5-MAPDI * 6-MAPDB * IBF5MAP IBF5MAP (5-MAPP) i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-MAPDI
5-MAPDI (also known as Indanylmethylaminopropane or IMP) is an entactogenic amphetamine derivative which is structurally related to MDMA as well as to dihydrobenzofuran derivatives such as 5-MAPDB and 6-MAPDB, and has been sold as a designer drug. It has reportedly been sold over grey-market websites since around 2014, although the first definitive identification was not made until September 2016 by a forensic laboratory in Slovenia. See also * IBF5MAP IBF5MAP (5-MAPP) is a substituted amphetamine derivative which is structurally related to drugs such as MDMA and 5-MAPDI, though its pharmacology has not been studied in detail. It is a structural isomer of dihydrobenzofuran derivatives such as ... References {{Entactogens, state=expanded Substituted amphetamines Designer drugs Entactogens and empathogens ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Temporary Class Drug
A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The controlled drug legislation in these jurisdictions requires drug scheduling decisions to follow an evidence-based process, where the harms of the drug are assessed and reviewed so that an appropriate legal status can be assigned. Since many designer drugs sold in recent years have had little or no published research that could help inform such a decision, they have been widely sold as "legal highs", often for months, before sufficient evidence accumulates to justify placing them on the controlled drug schedules. This situation has been deemed to be undesirable, as every time a designer drug has been banned, novel compounds with similar effects have been quickly developed and brought to market, often with worse health consequences reported than the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
6-MAPDB
6-MAPDB (1-(2,3-dihydrobenzofuran-6-yl)-N-methylpropan-2-amine) is a chemical compound which might be an entactogenic drug. It is structurally related to drugs like 6-APDB and 6-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 6-MAPDB has never been studied to determine its pharmacological activity, though it is the N-methyl derivative of 6-APDB which is known to be a selective serotonin releaser. Legality 6-MAPDB was banned in the UK in June 2013 as a temporary class drug along with 9 other related compounds, despite having never been sold as a street drug itself. This was due to concerns that it would have similar effects to drugs such as 6-APB that had been widely sold already, and 6-MAPDB might therefore be likely to become used recreationally also, if it were not banned preemptively. See also * 5-MAPDB * 5-MAPDI * IBF5MAP IBF5MAP (5-MAPP) is a substituted amphetamine derivative which is structurally related to drugs such as MDMA and 5-MA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
IBF5MAP
IBF5MAP (5-MAPP) is a substituted amphetamine derivative which is structurally related to drugs such as MDMA and 5-MAPDI, though its pharmacology has not been studied in detail. It is a structural isomer of dihydrobenzofuran derivatives such as 5-MAPDB and 6-MAPDB, but instead has an unusual phthalane core structure. See also * Citalopram * Substituted methylenedioxyphenethylamine Substitution reaction, Substituted methylenedioxy- phenethylamines (MDxx) are a large chemical class of derivative (chemistry), derivatives of the phenethylamines, which includes many psychoactive drugs that act as entactogens, psychedelic drug, ... References {{Entactogens, state=expanded Substituted amphetamines Designer drugs Entactogens and empathogens Isobenzofurans ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMA
3,4-Methylenedioxymethamphetamine (MDMA), commonly seen in Tablet (pharmacy), tablet form (ecstasy) and crystal form (molly or mandy), is a potent empathogen–entactogen with stimulant properties primarily used for Recreational drug use, recreational purposes. The desired effects include altered Sense, sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last 3 to 6 hours. MDMA was first developed in 1912 by Merck Group, Merck. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly associated with dance party, dance parties, raves, and electronic dance music. It may be Cutting agent, mixed with other substances such as ephedrine, amphetamine, and methamphetamine. In 2016, about 21 million people between the ages of 15 and 64 used ecstasy (0.3% of the world population). This was broadly similar to the percentage of people who use cocaine ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-APDB
5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB, 3-Desoxy-MDA, EMA-4) is a putative entactogen drug of the phenethylamine and amphetamine classes. It is an analogue of MDA where the heterocyclic 3-position oxygen from the 3,4-methylenedioxy ring has been replaced by a methylene bridge. 6-APDB is an analogue of 5-APDB where the 4-position oxygen has been replaced by a methylene bridge instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA. In animal studies, 5-APDB's effects generalize most closely to non-stimulant MDMA analogues such as MBDB and MMAI, while producing no substitution for LSD or amphetamine. ''In vitro'' studies show that 5-APDB acts as a highly selective serotonin releasing agent (SSRA), with IC50 values of 130 nM, 7,089 nM, and 3,238 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively. In contrast, 6-APDB is more balanced on the th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-MAPB
5-MAPB (1-(benzofuran-5-yl)-''N''-methylpropan-2-amine) is an entactogenic designer drug similar to MDMA in its structure and effects. Legal Status Canada 5-MAPB is not listed itself in the CDSA but since it is structurally related to MDMA it may be considered illegal in Canada, although this has not been tested in court. China As of October 2015 5-MAPB is a controlled substance in China. Luxembourg As of July 2021, 5-MAPB is not cited in the list of prohibited substances. Therefore, it is still a legal substance. United Kingdom 5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs. Pharmacokinetics Metabolism and toxicity Little formal knowledge exists on 5-MAPB. It does not form the alpha-methyldopamine metabolite that contributes to the neurotoxicity of MDM ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Selective Serotonin Releaser
A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A selective serotonin releasing agent (SSRA) is an SRA with less significant or no efficacy in producing neurotransmitter efflux at other types of monoamine neurons. SSRAs have been used clinically as appetite suppressants, and they have also been proposed as novel antidepressants and anxiolytics with the potential for a faster onset of action and superior efficacy relative to the selective serotonin reuptake inhibitors (SSRIs). A closely related type of drug is a serotonin reuptake inhibitor (SRI). Examples and use of SRAs Amphetamines like MDMA, MDEA, MDA, and MBDB, among other relatives (see MDxx), are recreational drugs termed entactogens. They act as serotonin-norepinephrine-dopamine releasing agents (SNDRAs) and also agonize serotonin receptors such as those in the 5-HT2 subfamily. Fenfluramine, chlorphentermine, and aminorex, which are also amphet ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Methamphetamines
Methamphetamine (contracted from ) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine. ''Methamphetamine'' properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms. It is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine. Both racemic methamphetamine and dextromethamphetamine are illicitly trafficked and sol ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects, and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human trials, the use of some of these drugs may result i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
